Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.62 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.50 |
| ▸ | RPA1 | P27694 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL278149 | 0.99 | CNR1 (0.61) | CNR1PTGS2CYP1A2HIF1ACNR2 | |
| SCHEMBL16197705 | 0.94 | CNR1 (0.57) | CNR1PTGS2CYP1A2HIF1ACNR2 | |
| SCHEMBL29838955 | 0.94 | CYP1A2 (0.57) | CNR1PTGS2CYP1A2HIF1ACNR2 | |
| SCHEMBL277080 | 0.90 | CNR1 (0.54) | CNR1PTGS2CYP1A2HIF1ACNR2 | |
| SCHEMBL4885515 | 0.90 | RPA1 (0.57) | CNR1PTGS2CNR2RPA1 | |
| SCHEMBL6341478 | 0.89 | PTGS2 (0.79) | CNR1PTGS2PTGS1CA1CA2 | |
| SCHEMBL278148 | 0.88 | CNR1 (0.62) | CNR1PTGS2CNR2PTGS1 | |
| SCHEMBL276776 | 0.87 | CNR1 (0.57) | CNR1PTGS2PTGS1CA1CA2 | |
| SCHEMBL276779 | 0.85 | CNR1 (0.49) | CNR1PTGS2CYP1A2HIF1ACNR2 | |
| SCHEMBL277227 | 0.83 | CNR1 (0.48) | CNR1PTGS2CNR2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133904-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity | JENRIN DISCOVERY, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| EP-2182807-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | Jenrin Discovery (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009033125-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20090069329-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2009-03-12 | — | — | US | disclosed |
| US-20080200527-A1 | Cannabinoid Receptor Modulators | CAREX SA (FR) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200527-A1 | Cannabinoid Receptor Modulators | CNR1, CNR2, HCRTR2 | CNR1 1/4885PTGS2 2767/4885CYP1A2 1319/4885 |
| US-20090069329-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | CNR2, CNR1, GPR119 | CNR1 2/4885PTGS2 1821/4885CYP1A2 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.